Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 16, 2020

1Health.io launches self-collection kits for Covid-19 diagnosis

Health platform 1Health.io has launched telehealth supervised self-collection kits for Covid-19 diagnosis in collaboration with its lab partners.

Health platform 1Health.io has launched telehealth supervised self-collection kits for Covid-19 diagnosis in collaboration with its lab partners.

The test enables patients to have their saliva collected in a special kit during a telehealth session under the remote supervision of a care provider. The test results are digitally delivered to the ordering healthcare provider within three to four days.

It reduces the demand for consumption of nasal swabs, which are in shortage across the hospitals in the US.

Furthermore, the test will enable doctors and rural clinics with limited access to local lab equipment to secure test for their patients with reduced incidence of secondary infection.

1Health.io CEO Mehdi Maghsoodnia said: “Our focus as a team is to help bring fast and reliable testing to everyone universally.

“We are hoping that by providing an end-to-end platform that performs testing, contact tracing, telehealth and clinical supervision, we can enable our healthcare providers to rapidly obtain tests for their patients regardless of their location.”

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

The company also reported the immediate availability of 50,000 Covid-19 test kits that are the US Food and Drug Administration (FDA)-approved for telehealth or other provider-supervised self-collection.

1Health.io also plans to scale up the production to provide 300,000 test kits by May to increase testing capacity in the US.

Initially, the kits will be provided to hospital systems and doctors who want to remotely collect specimens from Covid-19 symptomatic patients within clinical settings.

The company said it has received inbound demand from numerous state and hospital systems for its test kit capacity and has committed to maintaining price transparency in the process.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU